See more : Mitachi Co., Ltd. (3321.T) Income Statement Analysis – Financial Results
Complete financial analysis of The Oncology Institute, Inc. (TOI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Oncology Institute, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Kyowa Kirin Co., Ltd. (KYKOF) Income Statement Analysis – Financial Results
- Air Canada (AC.TO) Income Statement Analysis – Financial Results
- WinVest Acquisition Corp. (WINVW) Income Statement Analysis – Financial Results
- Cocrystal Pharma, Inc. (COCP) Income Statement Analysis – Financial Results
- Shree Cement Limited (SHREECEM.BO) Income Statement Analysis – Financial Results
The Oncology Institute, Inc. (TOI)
About The Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 324.24M | 252.48M | 203.00M | 187.51M | 155.41M | 113.16M |
| Cost of Revenue | 264.67M | 200.39M | 162.16M | 150.64M | 125.46M | 86.88M |
| Gross Profit | 59.57M | 52.09M | 40.85M | 36.88M | 29.94M | 26.28M |
| Gross Profit Ratio | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% | 23.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 309.17K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 41.59M | 0.00 | 0.00 |
| SG&A | 113.85M | 119.69M | 83.37M | 41.90M | 29.64M | 20.39M |
| Other Expenses | 22.74M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| Operating Expenses | 136.59M | 124.10M | 86.71M | 45.07M | 32.59M | 21.49M |
| Cost & Expenses | 401.26M | 324.49M | 248.86M | 195.71M | 158.05M | 108.37M |
| Interest Income | 0.00 | 4.08M | 320.00K | 254.15K | 3.38K | 0.00 |
| Interest Expense | 6.78M | 4.08M | 320.00K | 347.06K | 3.38K | 1.59K |
| Depreciation & Amortization | 5.87M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| EBITDA | -70.45M | 8.40M | -7.94M | -11.29M | 307.11K | 9.08M |
| EBITDA Ratio | -21.73% | -26.57% | -20.43% | -6.02% | 0.20% | 5.27% |
| Operating Income | -77.02M | -72.01M | -45.86M | -8.20M | -2.63M | 4.79M |
| Operating Income Ratio | -23.75% | -28.52% | -22.59% | -4.37% | -1.70% | 4.23% |
| Total Other Income/Expenses | -6.09M | 81.86M | 34.26M | -6.62M | 6.63K | 71.18K |
| Income Before Tax | -83.10M | 1.90M | -11.60M | -14.81M | -2.64M | 4.86M |
| Income Before Tax Ratio | -25.63% | 0.75% | -5.71% | -7.90% | -1.70% | 4.30% |
| Income Tax Expense | -36.00K | 247.00K | -671.00K | -492.82K | 1.38M | 912.75K |
| Net Income | -83.07M | 1.66M | -10.93M | -14.32M | -4.02M | 3.95M |
| Net Income Ratio | -25.62% | 0.66% | -5.38% | -7.64% | -2.59% | 3.49% |
| EPS | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| EPS Diluted | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| Weighted Avg Shares Out | 73.75M | 72.79M | 66.23M | 59.12M | 64.45M | 28.75M |
| Weighted Avg Shares Out (Dil) | 73.75M | 80.61M | 66.23M | 59.12M | 64.45M | 28.75M |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / September 18, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / September 17, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 10, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / September 9, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
Source: https://incomestatements.info
Category: Stock Reports